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Abstract
Purpose—To estimate lifetime risk of receiving an HIV diagnosis in the United States if existing 
infection rates continue.
Methods—We used mortality, census, and HIV surveillance data for 2010–2014 to calculate age-
specific probabilities of an HIV diagnosis. The probabilities were applied to a hypothetical cohort 
of 10 million live births to estimate lifetime risk.
Results—Lifetime risk was 1 in 68 for males and 1 in 253 for females. Lifetime risk for men was 
1 in 22 for blacks, 1 in 51 for Hispanic/Latinos, and 1 in 140 for whites; and for women was 1 in 
54 for blacks, 1 in 256 for Hispanic/Latinas, and 1 in 941 for whites. By risk group, the highest 
risk was among men who have sex with men (1 in 6) and the lowest was among male 
heterosexuals (1 in 524). The majority of the states with the highest lifetime risk were in the south.
Conclusions—The estimates highlight different risks across populations and the need for 
continued improvements in prevention and treatment. They can also be used to communicate the 
risk of HIV infection and increase public awareness of HIV.
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INTRODUCTION
Approximately 1.2 million people were living with HIV infection in the United States at the 
end of 2012, 12.8% of whom were unaware of their infection (1). In addition, disparities 
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continue to persist with men who have sex with men, and blacks/African Americans 
(hereafter referred to as blacks) and Hispanics/Latinos who make up the majority of persons 
with HIV diagnosed in 2013 (2). For HIV prevention messages to be effective, it is 
important to communicate clearly the burden of disease and who is at risk. One useful 
method to describe the burden of disease is to estimate lifetime risk, which is often 
expressed in terms of the number of people who would need to be followed throughout their 
lives to observe one occurrence of the disease. This method may be a useful tool for 
clinicians, outreach workers, and policy makers when describing the burden of HIV because 
it can be more readily understood by the general public. Lifetime risk is often used to 
describe the risk of cancer, and is sometimes used for HIV diagnosis.
Previous estimates of the lifetime risk of receiving an HIV diagnosis were generated using 
surveillance data for 2004–2005 from 33 states that had implemented confidential, name-
based HIV reporting at that time (3). However, these estimates did not include all 
jurisdictions in the nation, and some trends in HIV have changed since that time, such as a 
decrease in HIV diagnosis rates among women (2). It is now also possible to determine 
lifetime risk of HIV diagnosis by risk group based on recently published estimates of the 
proportion of the United States population who are men who have sex with men (MSM), 
who comprise the majority of persons with HIV, as well as persons at risk for HIV due to 
injection-drug use or heterosexual contact (4–6). In addition, data on HIV diagnoses are now 
available from all 50 states and the District of Columbia. This analysis presents lifetime and 
age-conditional risk estimates using data from 2009–2013 by race/ethnicity, sex, and risk 
group as well as state-level lifetime risk estimates.
METHODS
Age-specific HIV diagnosis, mortality, and population data were used to derive lifetime and 
age-specific risk estimates of receiving a diagnosis of HIV infection. Data on HIV diagnoses 
were obtained from the Centers for Disease Control and Prevention’s (CDC) National HIV 
Surveillance System (NHSS). Since the early 1980s, cases of stage 3 (AIDS) HIV infection 
have been reported to NHSS by all states, the District of Columbia, and U.S. dependent 
areas. In 1994, CDC implemented a uniform system for national, integrated HIV and AIDS 
surveillance, and over time as jurisdictions implemented confidential, name-based HIV 
reporting their data was reported to NHSS. By 2008, all 50 states and the District of 
Columbia (D.C.) were reporting cases of HIV infection to NHSS. To determine the number 
of HIV diagnoses, we used data for the most recent 5-years available (2010–2014) from the 
50 states and D.C. The year of HIV diagnosis was based on the earliest reported date of 
diagnosis.
General and HIV-specific mortality data were obtained from information on death 
certificates reported to CDC’s National Centers for Health Statistics for the 50 states and 
D.C. The most recent NCHS mortality data available were for the year of 2014. Population 
data were obtained from the Vintage 2014 postcensal estimates file (for years 2010–2014) 
from the U.S. Census Bureau (7). Our final data consisted of HIV diagnosis data, general 
and HIV-specific mortality data, and population data from the 50 states and DC between 
2010 and 2014.
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The numbers of HIV diagnoses and non-HIV deaths between 2010 and 2014 were 
determined for each single-year age group. The numbers of HIV diagnoses were adjusted for 
missing transmission category (8). The HIV diagnosis and non-HIV death rates were derived 
by dividing the HIV diagnoses and non-HIV death counts at each age by the population 
denominator for that age. These rates were converted to probabilities of a diagnosis of HIV 
at a given age, conditional on never having acquired HIV prior to that age using a competing 
risks method, i.e. dying before acquiring an HIV infection (9, 10). The competing risks were 
assumed to be independent of the event of interest, i.e., HIV diagnosis. The probabilities 
were applied to a hypothetical cohort of 10 million live births and estimates were derived for 
each age in the hypothetical cohort of the number alive and HIV-free at the beginning of the 
interval; the number of newly diagnosed HIV cases in the interval; the number of non-HIV 
deaths in the interval among the HIV-free population; and the cumulative probability of 
receiving a diagnosis of HIV infection from birth. The lifetime risk estimate is the 
cumulative probability of receiving a diagnosis of HIV from birth. The inverse of lifetime 
risk renders an estimate for the number of persons who would need to be followed 
throughout the specified life years to observe one HIV diagnosis (reported as 1 in n). Age-
conditional risks of receiving an HIV diagnosis were also computed. Age-conditional risk 
measures were the probabilities of an individual of a specified age receiving a diagnosis of 
HIV infection within a certain number of years, such as the risk of a diagnosis of HIV in the 
next 10 years among those alive and HIV-free at age 30. Compared to lifetime risk estimates, 
age-conditional risk estimates are less restricted by long-term extrapolation of the current 
rates, and they provide information for specific ages. Confidence intervals (CI) were 
estimated using a generalized gamma method originally developed for linear combinations 
of independent Poisson random variables (9). The lifetime risk estimates and age-conditional 
risk estimates were calculated for the entire population, as well as each combination of sex, 
race/ethnicity, and HIV-risk group. The lifetime risk estimates were also calculated for each 
state. All the calculations were conducted in DevCan 6.7.3 software (10), developed by the 
National Cancer Institute.
The estimates for risk groups, MSM, people who inject drugs (PWID) and heterosexuals, 
required further assumptions because this information is not noted in the census or mortality 
data. We used previously published estimates of the population proportions for these three 
risk groups, and applied them to the census and mortality data (4–6, 11). For example, an 
estimated 6.55% of the male population are MSM (6.9% MSM (6) – 0.35% MSM/PWID 
(11)). This percent was applied to the adult male population in the census data and any-cause 
mortality data, but we also needed the proportion of deaths among people with HIV 
attributed to each risk group. We obtained this proportion from the NHSS data (2010–2014) 
and applied this percent to the deaths with any mention of HIV on the death certificate (HIV 
deaths) in the mortality data. The number of HIV deaths was then subtracted from the total 
number of deaths in each risk group to get the number of non-HIV deaths for each age.
For each age:
A = # of all deaths in mortality dataset
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P = population proportion for risk group based on published estimates (4–6, 11)
B = # of deaths among persons with HIV in the risk group, NHSS data
C = # of all deaths among persons with HIV, NHSS data
D = # of HIV deaths in mortality dataset
The P was based on the published age-group estimates regardless of race or ethnicity. In 
addition, lifetime risk by risk group was based on following a cohort of people from age 13 
instead of from birth.
RESULTS
In the United States, 207,229 people with HIV were diagnosed during 2010–2014. Overall, 
the lifetime risk of a diagnosis of HIV was 0.95% (95% CI: 0.94–0.95). This means that to 
observe one HIV diagnosis, 106 (95% CI: 105–106) infants would need to be followed over 
a lifetime, assuming that the 2010–2014 HIV diagnosis and death rates remain constant over 
their lifetime.
The lifetime risk for males and females was 1 in 68 and 1 in 253, respectively (Table 1). 
Among both males and females, blacks had the highest lifetime risk (males: 1 in 22; 
females: 1 in 54). The lifetime risk among Hispanic/Latino males was 1 in 51 and, among 
Hispanic/Latino females, it was 1 in 256. Among males and females, the lowest risk was 
among Asians (males: 1 in 176; females: 1 in 943).
The risk group with the highest lifetime risk was MSM (1 in 6) with black MSM (1 in 2) and 
Hispanic/Latino MSM (1 in 5) having a higher risk than white MSM (1 in 11; Table 1). 
Female PWID (1 in 26) had a higher lifetime risk than male PWID (1 in 43) as did 
heterosexual females (1 in 266) compared to heterosexual males (1 in 524). Within each risk 
group blacks had the highest lifetime risk.
By state, the lifetime risk ranged from 1 in 674 in Montana to 1 in 17 in the District of 
Columbia. (Table 2). The states with the highest lifetime risks were Maryland (1 in 56), 
Georgia (1 in 57), Florida (1 in 58), and Louisiana (1 in 58).
Table 3 presents the 10-year age-conditional risks of an HIV diagnosis among HIV-free 
males and females for select ages. These numbers indicate how many people would need to 
be followed for the next 10 years to observe one HIV diagnosis among those who are HIV-
free at a specific age. Among males, those aged 20 years had the highest risk of an infection 
in the next 10 years (1 in 192). This was true for black, Hispanic/Latino, and white males 
(Table 3). Among females, the highest risk was at age 30 (1 in 952). By race/ethnicity, the 
risk among white and black females was highest at age 30 while the risk among Hispanic/
Latino females was highest at age 40. Among MSM, risk was highest at age 20 and risk 
decreased with age. The opposite pattern was true among male PWID; the risk increased 
with age with the highest risk at age 50. Female PWID had the lowest 10-year risk at age 40. 
The highest risk among male heterosexuals was at age 40, and, among female heterosexuals, 
it was at age 20.
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Lifetime risk increases with age (Figure 1), although most of the risk is accumulated before 
age 50 (risk by age 50, 1.24% for males and 0.31% for females). For males this represents 
84% of their lifetime risk and, for females, it is 78% of their risk.
DISCUSSION
Overall, the lifetime risk of HIV diagnosis was 0.95%, which was a 26% decrease from the 
previous estimate based on data from 2004–2005 (1.29%) (3). The risk decreased among 
both males (21%) and females (44%). There was also a decrease in lifetime risk among all 
race/ethnicities, but severe disparities still persisted. Among males, the lifetime risk among 
blacks was more than six times the risk among whites and the risk among Hispanics/Latinos 
was nearly three times the risk of whites. The risk among black females was 17 times the 
risk of white females, and the risk among Hispanic/Latino females was more than three 
times the risk for white females. Lifetime risk for MSM and male PWID were 88 and 12 
times the risk for male heterosexuals, respectively.
Another shift from previous estimates was the age at highest risk among males. The 2004–
2005 estimates showed the highest risk of being diagnosed in the next ten years was among 
35 year olds (3). Our estimates now show the highest risk at 20 years old. This could be the 
result of increases in diagnoses among young MSM and decreases among older MSM (12). 
Among females, the highest risk of being diagnosed in the next ten years was at age 30 
years, which is the same as the previous estimate (3). It should be kept in mind when 
comparing the current estimates to the previous estimates (2004–2005) that the previous 
estimates were only based on data from 33 jurisdictions, which accounted for 63% of 
diagnoses, so the previous estimates may have been an over or underestimate of the actual 
risk.
This paper also reports lifetime risk by state for the first time, which allows states to 
communicate about HIV risk at the local level. There was a wide range in estimates of 
lifetime risk by state. The states with the highest lifetime risk were all in the South, which 
accounts for the highest morbidity of HIV in the United States (2). The area with the highest 
risk was the District of Columbia (1 in 17). However, the District of Columbia is a city, so 
comparisons to states should be made with caution. The majority of persons with HIV 
diagnosed in a year live in metropolitan statistical areas (2).
Another new element of this paper is the lifetime risk by risk group, which is now possible 
because of published population size estimates for these groups (4–6). This allows us to 
better describe the risk among groups such as MSM and PWID. The lifetime risk was very 
high among MSM, and, in particular, black MSM with a probability of a diagnosis in their 
lifetime at 41%. This result is lower than a previous analysis in which the estimated HIV 
prevalence among a cohort of young, black MSM was 61% by age 40 (13). The estimated 
prevalence among all MSM in an earlier analysis was 41% (14), which is much higher than 
our estimated probability of a diagnosis (17%). However, both of these previous analyses 
were based on meta-analyses of several studies including community-based studies and 
studies conducted at HIV testing sites and STD clinics (13, 14), which may represent a 
higher risk population. MSM comprise about 78% of men infected with HIV each year (12) 
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and have a very high rate of receiving a diagnosis of HIV infection compared to males in 
other risk groups: 672 per 100,000 (6) compared to 49 per 100,000 male PWID (4) and 3.6 
per 100,000 male heterosexuals (5).
Our analysis is subject to some limitations. First, it is based on diagnosis data, not incidence. 
Therefore, our estimates are for receiving a diagnosis of HIV, not acquiring a new HIV 
infection, which can occur years before the diagnosis. While incidence estimates are now 
available for the United States, they rely on extrapolation from areas with incidence 
surveillance and incidence estimates are not available for individual states. On the other 
hand, reliable data on HIV diagnoses are available and estimates are based on data reported 
by all 50 states and the District of Columbia. In addition, the death certificate data may not 
have been accurate for all deaths. In particular, HIV may have been omitted from some death 
certificates of people with diagnosed HIV. Additionally, risk group estimates of lifetime risk 
are based on estimates of population size. If these estimates are an under or over estimate of 
the population size, the lifetime risk estimate would also be over or under estimated, 
respectively. It should also be noted that due to rounding, the 1 in n number can reflect a 
wide range of probabilities among groups with a high prevalence of infection (e.g., the 1 in 2 
lifetime risk among black MSM reflects a probability of 0.41, but it could be reflective of a 
probability as low as .41 and as high as .66). Lastly, some sub-groups had a small number of 
HIV diagnoses, such as Native Hawaiian/other Pacific Islander PWID, resulting in wide 
confidence intervals, so their lifetime risk estimates should be interpreted with caution.
One key caveat of this analysis is that it assumes no change in trend over a person’s lifetime 
from the 2010–2014 levels, but trends in HIV diagnosis have changed, so these numbers 
should be updated regularly. It should be noted that these are projections based on rates 
during 2010–2014 and do not account for cohort effects or changes in diagnosis rates over 
time. They serve as a method to communicate the level of risk currently being experienced 
in different communities, and are not a guarantee of what will occur in the future. Lifetime 
risk has decreased from previous estimates, in part due to prevention efforts such as, 
prevention of mother-to-child transmission and highly-active antiretroviral therapy. Through 
continued prevention efforts, including Treatment as Prevention and pre-exposure 
prophylaxis (PrEP), these rates will hopefully continue to change, resulting in a lower 
realized lifetime risk. In addition, it is important to monitor disparities to ensure that 
prevention efforts reduce risk in all groups.
In summary, an estimated 1 in 106 people living in the United States have received or will 
receive a diagnosis of HIV infection during their lifetime. The risk of an HIV diagnosis 
among MSM is nearly 88 times the risk among male heterosexuals, and black MSM have 5 
times the risk of white MSM. Among females, the risk among blacks was 17 times that 
among whites, and this disparity was higher (20 times) among heterosexual females. The 
National HIV/ADS Strategy: Updated to 2020 calls for intensifying HIV prevention efforts 
in communities where HIV is most heavily concentrated by allocating public funding 
consistent with the geographic distribution of HIV and focusing on high-risk populations 
(15). The Strategy also seeks to reduce HIV-related disparities in communities at high risk 
for HIV infection. These data on lifetime risk can help describe the burden of HIV by state 
and by population, helping to inform programs and policies that target resources to those at 
Hess et al. Page 6
Ann Epidemiol. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
highest risk. In addition, the lifetime risk information can be used in communications to the 
public, as the Strategy calls for clear, specific, consistent, and scientifically up-to-date 
messages about HIV risks and prevention strategies be provided to educate all Americans 
about HIV risks, prevention, and transmission.
While lifetime risk based on data from 2010–2014 has decreased compared to earlier 
estimates using data from 2004–2005, continued improvements in prevention and care are 
needed so risk will continue to decline further. CDC’s approach to reducing HIV infections 
in the United States calls for high-impact prevention through a combination of interventions 
that are scientifically proven, cost-effective, and scalable (16). These include early diagnosis, 
prompt linkage to antiretroviral treatment, PrEP, condoms, and services for persons who 
inject drugs (17). CDC has increased its efforts in groups with the highest diagnosis rates, 
such as MSM, blacks/African Americans, and the South, with increased funding to health 
departments and community-based organizations that provide prevention interventions. The 
availability of lifetime risk estimates to be used by clinicians, outreach workers, and policy 
makers to more clearly communicate to the general public will hopefully aide efforts in 
reducing the incidence of HIV and decreasing disparities.
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Figure 1. 
Lifetime risk of HIV diagnosis, by age and sex, United States.
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